| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H20ClN3O.ClH |
| Molecular Weight | 306.231 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CCNC(=O)C1=CC=C(N)C(Cl)=C1
InChI
InChIKey=DMJHWHGTAHHHMU-UHFFFAOYSA-N
InChI=1S/C13H20ClN3O.ClH/c1-3-17(4-2)8-7-16-13(18)10-5-6-12(15)11(14)9-10;/h5-6,9H,3-4,7-8,15H2,1-2H3,(H,16,18);1H
| Molecular Formula | C13H20ClN3O |
| Molecular Weight | 269.77 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Declopramide is an apoptosis inducer. Also, it inhibits NFkappaB activation by inhibition of IkappaBbeta breakdown. In preclinical research, Declopramide demonstrated strong antitumor properties. It had been in phase II clinical trials for the treatment of colorectal cancer. However, this research has been discontinued.
CNS Activity
Originator
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Sourcing
PubMed
Sample Use Guides
Human monocytic cells (THP-1) were exposed to 3-chloroprocainamide (3-CPA) at doses 0.2, 1 and 5 mM just before 5 h stimulation with LPS to induce cytokine production. In this experiment, dose dependent inhibition of TNFalpha was paralleled by an equivalent inhibition of IL-1B, IL-6 and IL-8.
